Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry

The 21-gene Recurrence Score® (RS) assay is a validated prognostic/predictive tool in ER + early-stage breast cancer. However, clinical outcome data from prospective studies in RS ≥ 11 patients are lacking, as are relevant real-life clinical practice data. In this retrospective analysis of a prospec...

Descripción completa

Detalles Bibliográficos
Autores principales: Stemmer, Salomon M., Steiner, Mariana, Rizel, Shulamith, Soussan-Gutman, Lior, Ben-Baruch, Noa, Bareket-Samish, Avital, Geffen, David B., Nisenbaum, Bella, Isaacs, Kevin, Fried, Georgeta, Rosengarten, Ora, Uziely, Beatrice, Svedman, Christer, McCullough, Debbie, Maddala, Tara, Klang, Shmuel H., Zidan, Jamal, Ryvo, Larisa, Kaufman, Bella, Evron, Ella, Karminsky, Natalya, Goldberg, Hadassah, Shak, Steven, Liebermann, Nicky
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591181/
https://www.ncbi.nlm.nih.gov/pubmed/28900633
http://dx.doi.org/10.1038/s41523-017-0034-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591181/
https://www.ncbi.nlm.nih.gov/pubmed/28900633
http://dx.doi.org/10.1038/s41523-017-0034-6

Ejemplares similares